Enanta Pharmaceuticals Shareholders Affirm Management Direction

Enanta Pharmaceuticals (ENTA) has shared an update.

At Enanta’s recent Annual Meeting, shareholders cast their votes on several key proposals. They re-elected three Class II directors to serve until 2027, approved an amendment to the Equity Incentive Plan adding 975,000 shares, gave the thumbs up to executive compensation in the “say-on-pay” vote, and ratified the appointment of PricewaterhouseCoopers LLP as the independent accounting firm for the upcoming fiscal year. These decisions reflect shareholder confidence in the company’s management and strategic direction.

Find detailed analytics on ENTA stock on TipRanks’ Stock Analysis page.